December 29, 2011 — Navitoclax, a novel BH3 mimetic that blocks the function of BCL-2, has shown significant antileukemic activity in patients with chronic lymphocytic leukemia (CLL) in a phase 1 ...
FDA approves AbbVie’s VENCLEXTA + acalabrutinib for first-line CLL, the first all-oral fixed-duration option—see AMPLIFY data and what it means.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results